Valens GroWorks Corp. (CSE:VGW) (the “Company” or “Valens”), a multi-licensed, vertically integrated provider of cannabis products, is pleased to announce a multi-purpose partnership agreement (the “Agreement”) with SpeakEasy Cannabis Club Ltd. (CSE: EASY) (“SpeakEasy”). SpeakEasy shall also source an interim supply for Valens of 2,500 to 5,000 kilograms per month of suitable Cannabis material. 

“This partnership with SpeakEasy dovetails neatly with our expansion objectives. As a specialist in the extraction of cannabis, Valens creates some of the best oils in the world, with our proprietary process creating a product that is clear, transparent 100% cannabis oil. Companies like SpeakEasy are recognizing Valens’ expertise in the extraction business. By helping us secure a consistent quality product for our extraction process we jointly benefit to increase our distribution platform internationally. We are extremely excited to move forward with SpeakEasy” commented Valens CEO Tyler Robson.

Highlights of Proposed Partnership

Innovation and R&D Diversity

Valens’ Dealer’s License provides SpeakEasy with a platform to conduct research and development (“R&D”), store cannabis derivatives not covered under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), export cannabis oils and concentrates to international markets, and provides a facility to process natural health products. To accelerate and rationalize Valens’ exportation of cannabis products, SpeakEasy will introduce Valens to its international distribution network.

Expedited Sale to Domestic Markets

SpeakEasy and Valens, as part of the supply component of the Agreement, agree to secure a suitable partnership with an ACMPR LP sales licensee to accelerate domestic sales and marketing.

Export of Cannabis Oils to International Markets

Valens’ existing R&D and Dealer’s license will allow SpeakEasy to import and export key genetics, expediting joint product innovation and brand development on a global scale.

Secure Future Sales

Pending final approval under its ACMPR LP application, SpeakEasy will source an interim supply of Cannabis for Valens with 2,500 – 5,000 kilograms of suitable material per month, with a start date to be mutually determined.

Due Diligence Period

Valens has commenced a thirty (30) day due diligence period (the “Due Diligence Period”). The parties may mutually agree to an extension. Unless Valens provides notice to SpeakEasy on or before the expiry of the Due Diligence Period that the results of due diligence investigations are satisfactory and that it intends to proceed with the arrangement, the Agreement will automatically terminate without liability, unless such date and time is mutually extended by the parties in writing.

Each party will use commercially reasonable efforts to complete and execute a definitive agreement on or before the expiry of the Due Diligence Period.

“This deal with Valens is the first part of a series of arrangements that will bring both SpeakEasy and Valens to the forefront of the medical and recreational extract market both domestically and internationally, giving SpeakEasy a high volume of assured sales and providing Valens a consistent supply of high quality extract material produced at our site in Rock Creek.” stated Marc Geen, SpeakEasy CEO. “When Health Canada approves outdoor cultivation, because of our location SpeakEasy will be one of the lowest cost producers in the world.”

About SpeakEasy Cannabis Club

SpeakEasy Cannabis Club Ltd. is a late stage ACMPR applicant that is leveraging three generations of farming experience and the largest land package of an LP in Canada with 290 acres of the best agricultural land in British Columbia’s Southern interior region, known as the Napa Valley of weed country. SpeakEasy is disrupting the cultivation model by aggregating British Columbia’s best craft growers under one umbrella to produce the highest quality cannabis targeted at the highly sought after millennial recreational market.

SpeakEasy has submitted its extensive evidence package to Health Canada for its current 10,000 square foot facility and has commenced construction on its 80,000 square foot expansion facility. This 80,000 square foot facility will include growing, extraction and genetics labs.

About Valens GroWorks

Valens GroWorks Corp. is a vertically integrated provider of Canadian cannabis products, specializing in proprietary extraction techniques, with three wholly-owned subsidiaries located in Kelowna, BC. Subsidiary Valens Agritech has initiated cannabis production, processing and sales under a Health Canada Dealer’s Licence, which includes a supply agreement with Canopy Growth Corporation under their extensive CraftGrow distribution network. Subsidiary Supra THC Services is a Health Canada licensed cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant Based Medicine Analytics. Subsidiary Valens Farms is in the process of becoming a purpose-built facility in compliance with European Union (EU) Good Manufacturing Practices (GMP) standards, ensuring the product from this facility can be exported anywhere in world. For more information, please visit http://valensgroworks.com and

On behalf of the Board of Directors,

(signed) “Tyler Robson”
Chief Executive Officer

Notice regarding Forward Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.

SOURCE Valens GroWorks Corp.

For further information: Scott Young, Telephone: +1.705.888.2756

Click here to connect with Valens GroWorks Corp. (CSE:VGW) for an Investor Presentation.


Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less